Among all the CARs, CD19 CAR-T cell therapy for acute lymphoblastic leukemia (ALL) has shown the most promising results (>85%) as the CARs that respond to the pan-B-cell marker CD19 have shown robust efficiency. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.